Human Genome Sciences (HGS) starts at the molecular level for good health. Using its expertise in human genetics, the biopharmaceutical discovery and development firm is working on therapies for infectious and autoimmune diseases, cardiovascular disease, and cancer. Lead candidate Benlysta has gained FDA approval to treat systemic lupus and has since been extended into international markets. Benlysta was developed through a partnership with GlaxoSmithKline (which acquired HGS in 2012). In addition, the company has provided contract research and manufacturing services to other biotechs.